Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UNG | P13051 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NAT1 | P18440 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957694 | 1.00 | UNG (0.61) | UNGHDAC8HDAC6SLC7A5HDAC3 | |
| SCHEMBL15650707 | 0.88 | NPC1 (0.53) | UNGHDAC8HDAC6MEN1KMT2A | |
| SCHEMBL24527569 | 0.84 | HDAC8 (0.58) | UNGHDAC8HDAC6SLC7A5HDAC3 | |
| SCHEMBL27210087 | 0.83 | HDAC1 (0.65) | UNGHDAC8HDAC6HDAC3HDAC1 | |
| SCHEMBL5909363 | 0.82 | HDAC8 (0.83) | HDAC8HDAC6SLC7A5MEN1KMT2A | |
| SCHEMBL12651049 | 0.82 | CRBN (0.54) | HDAC8HDAC6TRIM24TRIM33MEN1 | |
| SCHEMBL9655260 | 0.81 | UNG (0.61) | UNGHDAC3HDAC1TRIM24TRIM33 | |
| SCHEMBL8129512 | 0.81 | HDAC8 (0.54) | HDAC8HDAC6SLC7A5HDAC3HDAC1 | |
| SCHEMBL6184692 | 0.81 | UNG (0.56) | UNGHDAC3HDAC1MEN1KMT2A | |
| SCHEMBL15652250 | 0.81 | ERN1 (0.58) | UNGHDAC3HDAC1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| CN-115260165-B | Benzo nitrogen-containing five-membered heterocyclic compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2024-08-06 | — | — | CN | disclosed |
| WO-2024114664-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114666-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITY (KR) | 2024-05-02 | — | — | US | disclosed |
| EP-4347588-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-C]PYRIDINE DERIVATIVES | JANSSEN Pharmaceutica NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| US-11932639-B2 | Fused ring heteroaryl compounds as ALK4/5 inhibitors | BISICHEM CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-117396476-A | Substituted phenyl-1H-pyrrolo [2,3-c ] pyridine derivatives | 詹森药业有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053112-A1 | PROCESS FOR PREPARING TRISUBSTITUTED PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| US-6624174-B2 | Especially for treating a neoplastic disease, retinopathy or age-related macular degeneration | NOVARTIS AG (CH) | 2003-09-23 | — | — | US | disclosed |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | disclosed |
| EP-0819129-B1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2000-08-02 | — | — | EP | disclosed |
| US-5981533-A | INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR AND CAN BE USED IN THE CASE OF EPIDERMAL HYPERPROLIFERATION (PSORIASIS) AND AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 1999-11-09 | — | — | US | disclosed |
| WO-1998014449-A1 | FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| EP-0819129-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031510-A1 | PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | TYMS, NUDT1, TYMP | UNG 47/4885HDAC8 3180/4885HDAC6 2180/4885 |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | UNG 4604/4885HDAC8 739/4885HDAC6 1630/4885 |
| US-11932639-B2 | Fused ring heteroaryl compounds as ALK4/5 inhibitors | ALK, FGFR4, ALKBH3 | UNG 1416/4885HDAC8 1877/4885HDAC6 2078/4885 |
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | UNG 2819/4885HDAC8 2023/4885HDAC6 1038/4885 |
| US-20240139125-A1 | BI-1 ANTAGONISTS AND THEIR USES | TMBIM6, RPS6KB1, RACK1 | UNG 3700/4885HDAC8 1854/4885HDAC6 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.